| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2803768 | Insulin | 2009 | 7 Pages |
Background: Increasing acceptance of basal-bolus insulin therapy for the control of diabetes mellitus (DM) has led to newer formulations of basal insulin analogues. The newest one is detemir.Objectives: Clinical evidence suggests that patients with type 2 DM require higher doses of detemir than other basal insulins to achieve equivalent glycemic control. This study examines evidence for greater dosing requirements and the implications of higher doses on the cost of insulin treatment.Methods: We performed a MEDLINE search for randomized, prospective studies comparing detemir with other basal insulins in patients with type 2 DM that were published in English between January 2000 and November 2008. The mean daily doses of basal and bolus insulin and the mean total daily insulin doses were determined. Overall weighted mean doses of the insulins were used to estimate the mean total daily insulin doses required for a 100-kg patient, and published 2008 US retail prices were used to estimate the retail costs of basal-bolus and basal-only insulin regimens.Results: Seven trials involving 3311 patients were identified in the literature search. The mean total daily insulin dose was 0.80 unit/kg for detemir-based regimens and 0.58 unit/kg for comparison regimens. For basal-bolus regimens, the estimated retail cost of the mean total daily insulin dose was $11.24 for detemir-based regimens compared with $8.99 for glargine-based regimens and $6.41 for neutral protamine Hagedorn (NPH)-based insulins. For basal-only regimens, the estimated retail cost of the mean total daily insulin dose was $8.23 for detemir compared with $5.19 for glargine and $2.35 for NPH.Conclusions: It is important for health care providers and patients to know that patients with type 2 DM may require substantially higher doses of detemir than other basal insulins. This should be considered when titrating the dose as well as in cost-benefit analyses of detemir versus other insulins.
